Delving into the Latest Updates on Calfactant with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Bovactant, Calf lung surfactant extract (CLSE), Calfactant (USAN)

+ [1]

Target-

Mechanism

Cell membrane permeability enhancers

Therapeutic Areas

Respiratory DiseasesOther Diseases

Active Indication

Respiratory Distress Syndrome, NewbornRespiratory Distress Syndrome

Inactive Indication

Acute Lung InjuryBronchiolitis

Originator Organization

ONY, Inc.

Active Organization

ONY, Inc.

Inactive Organization

ONY Agency LLC

Drug Highest PhaseApproved

First Approval Date

US (01 Jul 1998),

Respiratory Distress Syndrome

RegulationOrphan Drug (US)

Login to view timeline

Premature infants frequently have trouble breathing after birth. If the respiratory disorder is caused by surfactant deficiency or dysfunction, the disease is treated with a medication called surfactant that is given to the infant through a tube inserted into the windpipe. This study will compare the safety of two of the commonly used surfactants, poractant and calfactant,in the United States. Poractant has added chemicals called phospholipids which are known to cause inflammation and irritation in the body of premature infants. The investigators will compare this to another similar surfactant that does not contain these chemicals by looking at samples from the windpipe, while the tube is in place, and from blood tests in the first few days of life.
The investigators are hoping to learn whether calfactant is a safer therapeutic agent to treat respiratory distress syndrome in preterm infants compared to poractant.

Start Date01 Jul 2013

Sponsor / Collaborator

University of Missouri

100 Clinical Results associated with Calfactant

Login to view more data

100 Translational Medicine associated with Calfactant

Login to view more data

100 Patents (Medical) associated with Calfactant

Login to view more data

141

Literatures (Medical) associated with Calfactant

01 Jan 2025·Journal of Perinatology

High vs low CPAP strategy with aerosolized calfactant in preterm infants with respiratory distress syndrome

Article

Author: Gerday, E ; Kaluarachchi, D C ; Lasarev, M R ; Guthrie, S O ; Zapata, H A ; Minton, S ; Bahr, T

BACKGROUNDOptimal CPAP strategy to prevent CPAP failure defined as need for endotracheal intubation is unknown.OBJECTIVETo evaluate the risk of CPAP failure in infants treated with high vs low CPAP strategy while receiving aerosolized calfactant in the AERO-02 clinical trial and AERO-03 expanded access program.METHODSInfants born between 29 0/7 to 36 6/7 weeks were included. Comparisons were made between low and high CPAP groups (Low, 4-7 cm H₂O; High, 8-10 cm H₂O).RESULTSCPAP failure and pneumothorax were not different between the groups. Odds of CPAP failure were not different after adjustment for baseline characteristics (OR = 0.61; 95% CI: 0.29, 1.24).CONCLUSIONWe found no difference in CPAP failure among infants who received aerosolized calfactant that were treated with high vs low CPAP strategy. Efficacy of high CPAP strategy with aerosolized surfactant treatment needs to be evaluated in future studies.

01 Oct 2024·American Journal of Physiology-Lung Cellular and Molecular Physiology

Comparative biophysical study of clinical surfactants using constrained drop surfactometry

Article

Author: Zuo, Yi Y.

A thorough investigation into the biophysical properties of four animal-derived clinical surfactant preparations was conducted through constrained drop surfactometry under physiologically relevant conditions. This comparative study unveiled unique in vitro biophysical characteristics among these clinical surfactants, establishing correlations between their chemical composition, lateral film structure, and biophysical functionality. The acquired knowledge offers essential insights for the precise and personalized design of clinical surfactant for the treatment of respiratory distress syndrome and other respiratory conditions.

01 Jun 2024·The Journal of Pediatric Pharmacology and Therapeutics

Comparison of Efficacy and Pharmacoeconomic Outcomes Between Calfactant and Poractant Alfa in Preterm Infants With Respiratory Distress Syndrome

Article

Author: Schumann, Caitlin ; Le, Jennie ; Bui, Annie ; Jones, Treva ; Schwendeman, Clair

OBJECTIVESIn order to evaluate the impact of the surfactant of choice selection, primary end points were to compare the average number of doses per patient, need for mechanical ventilation on day 3, hospital length of stay, and in-hospital mortality between calfactant and poractant alfa in preterm infants with respiratory distress syndrome (RDS). Secondary outcomes included administration complications, development of bronchopulmonary dysplasia (BPD), and estimated average per patient cost among the study population.METHODSA retrospective chart review was performed at a level IV neonatal intensive care unit between January 2020 and December 2021 to compare the efficacy, safety, and pharmacoeconomic outcomes following a surfactant of choice switch from calfactant to poractant alfa in preterm infants with RDS.RESULTSFinal analysis included 253 premature infants with gestational age (GA) between 22 and 36 weeks who met inclusion criteria. A total of 118 patients who received calfactant required higher average number of doses, 1.5 vs 1.3 doses (p = 0.031), and had more administration complications than 135 patients who received poractant alfa (10.2 vs 2.2%, p = 0.008). The need for redosing, mechanical ventilation on day 3, hospital length of stay, in-hospital mortality, and development of BPD were comparable between both groups. However, the estimated average per patient cost for poractant alfa was 32% higher than calfactant ($1,901 vs $1,439, p <0.001).CONCLUSIONSDespite the pharmacoeconomic disadvantage, preterm infants who received poractant alfa needed fewer doses and were less likely to have administration complications compared with those who received calfactant.

100 Deals associated with Calfactant

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03317	Calfactant	R07AX	DB06415

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Respiratory Distress Syndrome, Newborn	TR	-	31 Oct 2018
Respiratory Distress Syndrome, Newborn	MY	-	31 Oct 2018
Respiratory Distress Syndrome	US	ONY, Inc.	01 Jul 1998

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchiolitis	Preclinical	US	ONY Agency LLC	12 Jan 2019
Bronchiolitis	Preclinical	US	ONY, Inc.	12 Jan 2019
Acute Lung Injury	Discovery	US	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02834624 (NEOSURF, CTgov)	Not Applicable	Respiratory Distress Syndrome	30	calfactant (Calfactant)	sgettpsjav(pdvxaksnuv) = hgvvrripij yzbgjlotoi (coecoxpyna, chleepcwkb - qbpyzgigve) View more	-	06 Jun 2017
				Poractant alfa (Poractant Alfa)	ofrvdjzfrg(mujhnjwjpo) = pvyyxfljwp aygmifgwum (gjqohzqxfl, hasmeehfxv - feckrmsdxq) View more
NCT00569530 (TOLSURFPilot, CTgov)	Phase 3	Bronchopulmonary Dysplasia \| Surfactant Dysfunction	85	Infasurf (ONY Inc.) (Treatment Surfactant (Infasurf) ONY, NY)	ffkuyomovq(tnxthzpdtc) = emrqpopzij tcqbrkdvzg (whxwbglkam, udqvhupgyc - mbkwfvesrz) View more	-	28 Jun 2016
				Sham (Sham (no Treatment))	ffkuyomovq(tnxthzpdtc) = bpwyegetkj tcqbrkdvzg (whxwbglkam, qsvnazrzck - edgsfyxewi) View more